Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients

BACKGROUND: Anti-tumour necrosis factor (anti-TNF) agents are associated with increased infection risk among elderly inflammatory bowel disease (IBD) patients, and thus, alternative biologics may be preferable. However, little comparative data exist on the safety and efficacy of vedolizumab and uste...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebeyehu, Gerum Gashaw, Fiske, Joseph, Liu, Eleanor, Limdi, Jimmy K., Broglio, Giacomo, Selinger, Christian, Razsanskaite, Violeta, Smith, Philip J., Flanagan, Paul K., Subramanian, Sreedhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702964/
https://www.ncbi.nlm.nih.gov/pubmed/36436155
http://dx.doi.org/10.1007/s10620-022-07770-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702964/
https://www.ncbi.nlm.nih.gov/pubmed/36436155
http://dx.doi.org/10.1007/s10620-022-07770-8

Ejemplares similares